Correlation between human immunodeficiency virus type 1 RNA levels in the female genital tract and immune activation associated with ulceration of the cervix

Journal of Infectious Diseases

Volumn 181, Issue 6, 2000, Pages 1950-1956

  Lawn, Stephen D ^a,d   Subbarao, Shambavi ^a   Wright Jr , Thomas C ^c   Evans Strickfaden, Tammy ^a   Ellerbrock, Tedd V ^a   Lennox, Jeffrey L ^b   Butera, Salvatore T ^a   Hart, Clyde E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c The New York Presbyterian Hospital   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENITAL ULCER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; LAVAGE; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; PRIORITY JOURNAL; UTERINE CERVICITIS; UTERINE CERVIX; UTERINE CERVIX DYSPLASIA; VIRUS LOAD; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS TRANSMISSION;

ADULT; ANTIGENS, CD14; FEMALE; GENITALIA, FEMALE; HIV-1; HLA-DR ANTIGENS; HUMANS; INTERLEUKIN-6; RECEPTORS, INTERLEUKIN-2; RNA, VIRAL; TUMOR NECROSIS FACTOR-ALPHA; ULCER; UTERINE CERVICAL DISEASES; UTERINE CERVICAL DYSPLASIA;

EID: 0034131051     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315514     Document Type: Article

References (45)

1. 1. Copeland KET, Heeney JE. T helper cell activation and human retroviral pathogenesis. Microbiol Rev 1996; 60:722-42.
2. 2. Wahl S, Orenstein JM. Immune stimulation and HIV-1 viral replication. J Leukoc Biol 1997; 62:67-71.
3. 3. Poli G, Fauci AS. The effect of cytokines and pharmacologic agents on chronic HIV infection. AIDS Res Hum Retroviruses 1992; 8:191-6.
4. 4. Vincenzi E, Poli G. Regulation of HIV expression by viral genes and cytokines. J Leukoc Biol 1994; 56:328-34.
5. 5. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 1996; 157:1271-8.
6. 6. Sulkowski MS, Chaisson RE, Karp CL, Moore RD, Margolick JB, Quinn TC. The effect of acute infectious illnesses on plasma human immunodeficiency virus type 1 load and the expression of serologic markers of immune activation among HIV-infected adults. J Infect Dis 1998; 178: 1642-8.
7. 7. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996; 334:1222-30.
8. 8. Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-infected individuals. J Exp Med 1995; 182:1727-37.
9. 9. Ostrowski MA, Krakauer DC, Li Y, et al. Effect of immune activation on the dynamics of human immunodeficiency virus replication on the distribution of viral quasispecies. J Virol 1998; 72:7772-84.
10. 10. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet 1997; 349:1868-73.
11. 11. Nakata K, Rom W, Honda Y, et al. M. tuberculosis enhances HIV-1 replication in the lung. Am J Respir Crit Care Med 1997; 155:996-703.
12. 12. Semba RD, Kumwenda N, Hoover DR, et al. Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 1999; 180:93-98.
13. 13. Royce RA, Sena A, Cates W, Cohen MS. Sexual transmission of HIV. N Engl J Med 1997; 336:1072-8.
14. 14. Wasserheit JN. Epidemiological synergy: relationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992; 19:61-77.
15. 15. Cameron DW, Simonsen JN, D'Costa JN, et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet 1989; 2:403-7.
16. 16. Dickerson MC, Johnston J, Delea TE, White A, Andrews E. The causal role for genital ulcer disease as a risk factor for transmission of human immunodeficiency virus. Sex Transm Dis 1996; 23:429-40.
17. 17. Hayes RJ, Schulz KF, Plummer FA. The cofactor effect of genital ulcers on the per-exposure risk of HIV transmission in sub-Saharan Africa. J Trop Med Hyg 1995; 98:1-8.
18. 18. Moss GB, Overbaugh J, Welch M, et al. Human immunodeficiency virus DNA in urethral secretions in men: association with gonococcal urethritis and CD4 cell depletion. J Infect Dis 1995; 172:1469-74.
19. 19. Clemetson DBA, Moss GB, Willerford DM, et al. Detection of HIV DNA in cervical and vaginal secretions. JAMA 1993; 269:2860-4.
20. 20. John GC, Nduati RW, Mbori-Ngacha D, et al. Genital shedding of human immunodeficiency virus type 1 DNA during pregnancy: association with immunosuppression, abnormal cervical or vaginal discharge, and severe vitamin A deficiency. J Infect Dis 1997; 175:57-62.
21. 21. Kreiss J, Willerford DM, Hensel M, et al. Association between cervical inflammation and cervical shedding of human immunodeficiency virus DNA. J Infect Dis 1994; 170:1597-601.
22. 22. Ghys PD, Fransen K, Diallo MO, et al. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote D'Iviore. AIDS 1997; 11:F85-F93.
23. 23. Wright TC, Subbarao S, Ellerbrock TV, et al. HIV-1 expression in the female genital tract associated with cervical inflammation and ulceration. Am J Obstet Gynecol 2000. In press.
24. 24. Belec L, Gheradi R, Payan C, et al. Proinflammatory cytokine expression in cervicovaginal secretions of normal and HIV-infected women. Cytokine 1995; 7:568-74.
25. 25. Hart CE, Lennox JL, Pratt-Palmore M, et al. Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis 1999; 179:871-82.
26. 26. Lawn SD, Shattock RJ, Acheampong JW, et al. Sustained plasma TNH-α and HIV-1 load despite resolution of other immune activation parameters during treatment for tuberculosis in Africans. AIDS 1999; 13:2231-7.
27. 27. Lawn SD, Roberts BD, Griffin GE, Folks TM, Butera ST. Cellular compartments of human immunodeficiency virus type 1 replication in vivo: determination by presence of virion-associated host proteins and impact of opportunistic infection. J Virol 2000; 74:139-45.
28. 28. Tremblay MJ, Fortin JF, Cantin R. The acquisition of host-encoded proteins by nascent HIV-1. Immunol Today 1993; 19:346-51.
29. 29. Bastiani L, Laal S, Kim M, Zolla-Pazner S. Host cell dependent alterations in envelope components of human immunodeficiency virus type 1 virions. J Virol 1997; 71:3444-50.
30. 30. Beutler B, Cerami A. The common mediator of shock, cachexia, and tumor necrosis. Adv Immunol 1988; 42:213-31.
31. 31. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990; 8:253-78.
32. 32. Nuovo GJ, Forde A, MacConnell P, Fahrenwald R. In situ detection of PCR-amplified HIV-1 nucleic acids and tumor necrosis factor cDNA in cervical tissues. Am J Pathol 1993; 143:40-48.
33. 33. Hashemi FB, Ghassemi M, Roebuck KA, Spear GT. Activation of human immunodeficiency virus type 1 expression by Gardnerella vaginalis. J Infect Dis 1999; 179:924-30.
34. 34. Klebanoff SJ, Watts DH, Meglin C, Headley CM. Lactobacilli and vaginal host defense: activation of the human immunodeficiency virus type 1 long terminal repeat, cytokine production, and NF-kB. J Infect Dis 1999; 179:
35. 35. Hedges SR, Sibley DA, Mayo MS, Hook EW, Russell MW. Cytokine and antibody responses in women infected with Neisseria gonorrhoeae effects of concomitant infections. J Infect Dis 1998; 178:742-51.
36. 1 women before and after treatment for vaginitis [abstract 467]. In: Abstracts of the 6th Conference on Retroviruses and Opportunistic Diseases (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999;155.
37. 37. Moriuchi M, Moriuchi H, Turner W, Fauci AS. Exposure to bacterial products renders macrophages highly susceptible to T-tropic HIV-1. J Clin Invest 1998; 102:1540-50.
38. 38. Pomerantz RJ, de la Monte SM, Donnegan SP, et al. Human immunodeficiency virus (HIV) infection of the uterine cervix. Ann Intern Med 1988; 108:321-7.
39. 39. Spira A, Marx PA, Patterson BK, et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 1996; 183: 215-25.
40. 40. Ziegler-Heitbrock HWL, Ulevitch RJ. CD14: cell surface receptor and differentiation marker. Immunol Today 1993; 14:121-5.
41. 41. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med 1990; 113:619-27.
42. 42. Van't Wout AB, Kootstra NA, Mulder-Kampinga GA, et al. Macrophagetropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 1994; 94: 2060-7.
43. 43. Rossio JL, Bess J, Henderson LE, Cresswell P, Arthur LO. HLA class II is functional in superantigen presentation to human T cells: implications for HIV pathogenesis. AIDS Res Hum Retroviruses 1995; 11:1433-9.
44. 44. Cantin R, Fortin J-F, Lamontagne G, Tremblay M. The acquisition of host-derived major histocompatibility complex class II glycoproteins by human immunodeficiency virus type 1 accelerates the process of virus entry and infection in human T-lymphoid cells. Blood 1997; 90:1091-100.
45. 45. Yamauchi H, Kobayashi E, Yoshida T, et al. Changes in immune-endocrine response after surgery. Cytokine 1998; 10:549-54.